HABP/VABP and Gram-Negative Resistance: Pathways to Early Effective Therapy

In this live, 2-hour symposium expert faculty review updates and challenges of optimized management of HABP and VABP including MDR Gram-negative infections. Following a didactic presentation and case discussion, faculty will answer your most pressing questions on gram-negative resistance.



Review of data and guidance on HABP/VABP and gram-negative resistance with case-based discussions of diagnostics and treatment (90 minutes)

Attendee questions answered by the experts (30 minutes)


Date / Time
Event Details


Lilian Abbo, MD, FIDSA

Associate Chief Medical Officer in Infectious Diseases
Jackson Health System
Professor of Infectious Diseases
Department of Medicine & Miami Transplant Institute
University of Miami Miller School of Medicine
Miami, Florida

Keith S. Kaye, MD, MPH

Division of Allergy, Immunology and Infectious Diseases
Professor of Medicine
Rutgers Robert Wood Johnson Medical School
New Brunswick, New Jersey

Jason M. Pogue, PharmD

Clinical Professor
Department of Clinical Pharmacy
University of Michigan College of Pharmacy
Infectious Diseases Clinical Pharmacist
Michigan Medicine
Ann Arbor, Michigan

Goal Statement

The goal of this activity is to improve the knowledge and competence of learners regarding the clinical role of new antimicrobial agents in the management of HABP and VABP.

Target Audience

This program is intended for physicians, pharmacists, and other healthcare professionals who care for patients with HABP and VABP.

Learning Objectives

  • Understand rapid detection strategies for HABP/VABP considering the burden of disease caused by multidrug-resistant Gram-negative infections and molecular epidemiology
  • Apply appropriate use of new antimicrobial agents and strategies for empiric and targeted therapy in multidrug-resistant, extensively drug–resistant, and difficult-to-treat–resistant Gram-negative HABP and VABP
  • Develop effective strategies to minimize time to effective therapy while incorporating antimicrobial stewardship principles


       Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education

CCO designates this continuing education activity for 2.0 contact hours (0.2 CEUs) of the Accreditation Council for Pharmacy Education. UAN: JA4008176-0000-22-008-L01-P

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.